Charles Schwab Investment Management Inc C4 Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 486,366 shares of CCCC stock, worth $899,777. This represents 0.0% of its overall portfolio holdings.
Number of Shares
486,366
Previous 482,929
0.71%
Holding current value
$899,777
Previous $2.75 Million
36.41%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CCCC
# of Institutions
125Shares Held
62.7MCall Options Held
651KPut Options Held
115K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$12.9 Million1.75% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.85MShares$12.7 Million9.58% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$11.2 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$9.02 Million0.28% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$8.42 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $90.5M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...